Exploring the effectiveness of crizotinib in the treatment of advanced lung cancer

Crizotinib (trade name: Xacori) is a targeted therapy drug targeting specific gene mutations. It is mainly used for the treatment of advanced lung cancer, especially anaplastic lymphoma kinase (ALK)-positive or ROS1-positive non-small cell lung cancer (NSCLC).

Multiple clinical trials have confirmed that for ALKpositive advanced NSCLC patients, crizotinib can significantly prolong the progression-free survival (PFS) and improve the objective response rate (ORR). For example, the PROFILE 1014 study showed that compared with chemotherapy, patients in the crizotinib group had significantly longer PFS and ORR was also higher.

For ROS1positive advanced NSCLC patients, crizotinib also showed significant therapeutic effects. The PROFILE 1001 study showed that the ORR of crizotinib in these patients was as high as 72%, and the median PFS was longer.

In addition to clinical trials, real-world studies have confirmed the effectiveness of crizotinib in the treatment of advanced lung cancer. These studies usually include a wider patient population and longer follow-up periods, and can more truly reflect the effects of the drug in actual clinical use.

A domestic multi-center retrospective study showed that ROS1fusion-positiveNSCLC patients received first-line crizotidine The median PFS of nil treatment reached 23 months, and the median overall survival (OS) up to 60 months.

Although crizotinib has shown significant effectiveness in the treatment of advanced lung cancer, patients still need to pay attention during use. Before using crizotinib, patients need to undergo genetic testing to determine whether their tumors have specific gene mutations such as ALK or ROS1. Only patients with these gene mutations are suitable for treatment with crizotinib.

Crizotinib may cause some adverse reactions, such as visual impairment, nausea, vomiting, diarrhea, etc. Patients need to closely monitor their physical condition during use and make necessary dose adjustments or symptomatic treatment under the guidance of a doctor.

Some patients may develop drug resistance after taking crizotinib for a period of time. At this time, doctors may consider switching to other targeted therapies or using combination treatment strategies to prolong the patient's survival.